09966 ALPHAMAB-B
- 4.810
- +0.140+3.00%
ALPHAMAB-B News
Corning Jerry Pharmaceutical-B (09966.HK) grants 1.18 million share options
Glonghui, April 23 | Corning Jerry Pharmaceutical-B (09966.HK) announced that on April 23, 2024, according to the initial public offering after-sales share option plan, the company has decided to grant 1.18 million share options to four eligible participants (that is, employees of the Group), at an exercise price of HK$4.350 per share. Under the restricted share award scheme, the company has decided to award a total of 130,000 award shares to two eligible participants (i.e. employees of the Group). The purpose of granting share options and rewarding shares is to: (i) recognize the share option grantor and reward the grantee's contributions to the Group; (i
Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting
Alphamab Oncology (HKG:9966) said it presented the phase-I clinical trial results of its cancer drug during a poster session at the American Association for Cancer Research annual meeting, according t
HER2 dual antibody ADC drug JSKN003 Australian Phase I clinical study data unveiled at 2024 AACR annual meeting
The findings of JSKN003 during the dose escalation period (Ia) were reported at this AACR conference. The treatment of advanced HER2 expression/metastatic solid tumors with JSKN003 showed encouraging efficacy signals, with an ORR of 100% in patients with HER2-positive breast cancer. The tolerability and safety are good, DLT has not occurred, and MTD has not been achieved. Suzhou, China, April 10, 2024 /PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced the company at the 2024 American Association for Cancer Research Annual Meeting (AACR 2024)
Corning Jerry Pharmaceutical-B (09966.HK): The latest results of the Phase I clinical study of JSKN003 for the treatment of advanced solid tumors with advanced HER2 expression presented at the 2024 AACR Annual Meeting
Gelonghui, April 10, 丨 Corning Jerry Pharmaceutical-B (09966.HK) announced that the results of the JSKN003 Phase I clinical study (study number: JSKN003-101) (“JSKN003-101”) for the treatment of patients with advanced/metastatic solid tumors (poster board number: 7; abstract number: CT179) were presented during the poster presentation period at the 2024 AACR Annual Conference held from April 5 to April 10, 2024.
Alphamab Oncology (HKG:9966) CEO Ting Xu's Holdings Dropped 9.7% in Value as a Result of the Recent Pullback
Key Insights Significant insider control over Alphamab Oncology implies vested interests in company growth The top 3 shareholders own 51% of the company Using data from analyst forecasts alongside
Alphamab Oncology Unit Renews Service Provision Contract, Annual Limits
Alphamab Oncology (HKG:9966) unit Jiangsu Alphamab Biopharmaceuticals has renewed an agreement to continue providing certain services to Suzhou Alphamab from April 2 to Dec. 31, 2025, a Tuesday filin
Changes in Hong Kong stocks | Corning Jerry Pharmaceutical-B (09966) rose more than 7% in the afternoon, losses during the year narrowed 35.35% year-on-year, and product revenue increased by more than 32%
The Zhitong Finance App learned that Corning Jerry Pharmaceutical-B (09966) rose more than 7% in the afternoon. As of press release, it had risen 6.45% to HK$4.62, with a turnover of HK$114.666 million. According to the news, Corning Jerry Pharmaceutical-B announced its 2023 annual results, with revenue of RMB 219 million, up 31.12% year on year; losses during the year were RMB 211 million, and losses narrowed 35.35% year over year. It is worth noting that in 2023, we achieved product revenue of 196 million yuan, an increase of 32.54% over the previous year. According to the announcement, the increase in revenue mainly comes from Sichuan Silu Kangrui Pharmaceutical
Corning Jerry Pharmaceutical-B (09966) announced its 2023 annual results, with a loss of 211 million yuan during the year, a year-on-year decrease of 35.35%
Corning Jerry Pharmaceutical-B (09966) announced its 2023 annual results, with revenue of RMB 219 million, an increase over the previous year...
ALPHAMAB-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Corning Jerry's subcutaneous drug JSKN033 completes first patient administration in Australia
SUZHOU, March 26, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that a clinical study for the treatment of advanced HER2 expression or metastatic solid tumors with advanced HER2 expression or metastatic solid tumors (study number JSKN033-101) has completed the first patient administration in Australia. Clinical research results have shown that ADC combined immunotherapy can improve treatment efficacy and significantly prolong survival. However, combination treatment increased the patient's infusion time and hospitalization time, and the occurrence of infusion reactions
The full study results of kn046 combined with chemotherapy for first-line treatment of metastatic non-small cell lung cancer were published in Cell sub-journal
SUZHOU, March 22, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the full results of the Phase II clinical study (KN046-202) of PD-L1/CTLA-4 combined with KN046 combined chemotherapy for first-line treatment of metastatic non-small cell lung cancer were published in Cell Reports Medicine (IF:14.3). Professor Zhang Li from Sun Yat-sen University Cancer Center is the corresponding author of this article, and Professor Zhao Yuanyuan is the first author. Corresponding author: Professor Zhang Li First Author: Zhao Yuanyuan
Corning Jerry Pharmaceutical-B (09966.HK) plans to hold a board meeting on March 28 to consider and approve annual results
Glonghui March 18 | Corning Jerry Pharmaceutical-B (09966.HK) announced that a board meeting will be held on March 28, 2024 (Thursday) to consider and approve the annual results and announcements of the company and its subsidiaries for the year ended 31 December 2023, and to deal with other matters.
ALPHAMAB-B: DATE OF BOARD MEETING
Corning Jerry will present clinical study data on JSKN003 treatment of HER2-expressing solid tumors at AACR 2024
SUZHOU, March 14, 2024/PRNewswire/ -- Corning Jerry Biopharmaceuticals (stock code: 9966.HK) announced that the Phase I clinical study data (study number: JSKN003-101) of the HER2 double antibody conjugate drug JSKN003 for the treatment of advanced HER2-expressing solid tumors in Australia (study number:) was selected for the 2024 American Association for Cancer Research Annual Meeting (AACR 2024) and will be announced in the form of a poster. The AACR Annual Conference is one of the oldest and largest scientific conferences in the world. It focuses on all aspects of high-quality and innovative oncology research and focuses on cancer leaders
Alphamab Oncology's (HKG:9966) 31% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Unfortunately for some shareholders, the Alphamab Oncology (HKG:9966) share price has dived 31% in the last thirty days, prolonging recent pain. For any long-term shareholders, the last month ends
Changes in Hong Kong stocks | Corning Jerry Pharmaceutical-B (09966) is now up nearly 5%. The company published clinical study results of kn046 combination therapy in Nature
Corning Jerry Pharmaceutical-B (09966) is now up nearly 5%. As of press release, it has risen 4.67% to HK$4.48, with a turnover of HK$11.091 million.
Alphamab Oncology's Market Cap Drops To HK$3.8b Leaving Insiders With Losses
The recent 15% drop in Alphamab Oncology's (HKG:9966) stock could come as a blow to insiders who purchased CN¥380.5m worth of stock at an average buy price of CN¥15.22 over the past 12 months. Inside
Alphamab Oncology Unit, 3D Medicines Grants Glenmark Unit License to Commercialize Sarcoma Injectable
Alphamab Oncology (HKG:9966) unit Jiangsu Alphamab and 3D Medicines (HKG:1244) granted Glenmark Pharmaceuticals' (NSE:GLENMARK, BOM:532296) Swiss unit, Glenmark Specialty, an exclusive license and a r
3D MEDICINES (01244) subsidiary and Corning Jerry (09966) granted Glenmark the exclusive license and sublicense for envorimab oncology indications
3D MEDICINES (01244) announced, Siludi Pharmaceuticals and Jiangsu Corning Jerry (licensor) and...
What Alphamab Oncology's (HKG:9966) P/S Is Not Telling You
Alphamab Oncology's (HKG:9966) price-to-sales (or "P/S") ratio of 21.8x might make it look like a strong sell right now compared to the Biotechs industry in Hong Kong, where around half of the compani
Analysis
Price Target
No Data
